ReviewJournal of inflammation research2025
Monoamine Oxidase B in Cancers: Implications for Therapeutics and Prognosis.
Review in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selegiline, a monoamine oxidase-B inhibitor as a modulator of metabolic reprogramming for cancer therapy: a review.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoamine oxidase B (MAOB) is an enzyme implicated in various physiological and pathological processes, particularly in the context of cancer. This review comprehensively examines the metabolic functions of MAOB within its dual implications in tumorigenesis. MAOB is significantly involved in regulating the levels of monoamines, including dopamine, and its dysregulation is associated with neurodegenerative diseases and cancer progression. Elevated MAOB activity has been linked to increased oxidative stress, contributing to tumor growth and metastasis through enhanced glycolysis and mitochondrial dysfunction. Furthermore, MAOB's influence on the tumor microenvironment is evidenced by its modulation of key signaling pathways such as NF-κB and PI3K/AKT, impacting immune response and tumor behaviors. This review discusses the distinct expression patterns of MAOB across various cancer types and its potential as a prognostic marker and therapeutic target. We outline ongoing efforts in the development of small molecule inhibitors of MAOB, investigating their mechanisms of action, efficacy, and potential combination therapies with traditional chemotherapeutics and immunotherapies. The integration of multi-omics approaches is emphasized as a future direction to further elucidate MAOB's role in cancer biology and refine personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.